Wells Fargo raises Health Catalyst price target to $1.75
Wells Fargo analyst Stan Berenshteyn maintained an Equal-Weight rating on Health Catalyst and raised the price target to $1.75 from $1, signaling a revised valuation outlook.
*this image is generated using AI for illustrative purposes only.
Wells Fargo analyst Stan Berenshteyn maintained an Equal-Weight rating on Health Catalyst (NASDAQ: HCAT) and increased the price target to $1.75 from $1. The adjustment reflects a revised valuation outlook for the healthcare data analytics provider.
The rating remains unchanged, indicating a neutral stance on the stock's performance relative to its sector peers. The new price target suggests potential upside based on the firm's analysis.
Rating and Price Target Details
| Metric | Value |
|---|---|
| Rating | Equal-Weight |
| Previous Price Target | $1 |
| New Price Target | $1.75 |
Health Catalyst specializes in providing data and analytics technology to healthcare organizations.
What specific factors drove the 75% increase in the price target despite the neutral rating?
How might Health Catalyst's valuation be impacted by current trends in healthcare data analytics adoption?
What upcoming milestones or earnings reports could influence the stock's performance relative to sector peers?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
